Barinthus Biotherapeutics

Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company developing novel immunotherapies designed to treat immunology and inflammatory conditions by guiding T cells to overcome autoimmunity and inflammatory diseases. The company's pipeline includes candidates such as VTP-200 for human papillomavirus-related cervical lesions and VTP-300 for chronic hepatitis B.